Neuralstem, Inc. announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis .
http://ift.tt/1uff3DS
http://ift.tt/1uff3DS
Stem Cell Research News: News on Stem Cell Research continually updated from thousands of sources around from the B Media Network.
No comments:
Post a Comment